DiMarco Aimee Natasha, Meeran Karim, Christakis Ioannis, Sodhi Vinpreet, Nelson-Piercy Catherine, Tolley Neil Samuel, Palazzo Francesco Fausto
Department of Surgery and Cancer, Imperial College, London, United Kingdom.
Department of Endocrine Surgery, Hammersmith Hospital, London, United Kingdom.
J Endocr Soc. 2019 Feb 20;3(5):1009-1021. doi: 10.1210/js.2018-00340. eCollection 2019 May 1.
The risks of primary hyperparathyroidism (pHPT) to pregnant women and their fetuses appear to increase commensurate with serum calcium levels. The management strategy for pHPT must be adapted in pregnancy and should reflect the severity of hypercalcemia. However, no guidelines exist to assist clinicians.
The experience of a high-volume multidisciplinary endocrine surgical service in treating a consecutive series of pregnant women with pHPT referred for parathyroidectomy is presented and data are compared with a nonpregnant cohort with pHPT. A review of pHPT and pregnancy outcomes in the literature is provided.
Seventeen pregnant women and 247 age range-matched nonpregnant women with pHPT were referred for surgery over 11 years. Mean serum calcium level was higher in the pregnant cohort (2.89 vs 2.78 mmol/L; = 0.03). Preoperative localization with ultrasound succeeded in eight pregnant women (47%) and sestamibi scanning did in two of six (33% imaged preconception), compared with 84 (34%) and 102 (42%) control subjects, respectively (not significant). Parathyroidectomy was performed under general anesthesia between 12 and 28 weeks' gestation with no adverse pregnancy outcomes resulting. Cure rate was 100% vs 96% in controls.
pHPT in pregnancy is a threat to mother and child. Medical management may be appropriate in mild disease, but in moderate to severe disease, parathyroidectomy under general anesthesia in the second trimester is safe. Localization using ionizing radiation/MRI is unnecessary, because surgical intervention in a high-volume multidisciplinary setting has excellent outcomes. Guidelines on the topic would assist clinicians.
原发性甲状旁腺功能亢进症(pHPT)对孕妇及其胎儿的风险似乎随着血清钙水平的升高而增加。pHPT的管理策略在孕期必须进行调整,且应反映高钙血症的严重程度。然而,目前尚无指导临床医生的指南。
介绍了一个高容量多学科内分泌外科治疗一系列连续转诊接受甲状旁腺切除术的妊娠合并pHPT患者的经验,并将数据与非妊娠的pHPT队列进行比较。同时提供了对文献中pHPT与妊娠结局的综述。
在11年期间,17例妊娠合并pHPT患者和247例年龄匹配的非妊娠pHPT患者被转诊接受手术。妊娠队列的平均血清钙水平更高(2.89 vs 2.78 mmol/L;P = 0.03)。超声术前定位在8例孕妇中成功(47%),6例中的2例(33%在孕前成像)进行了锝99m甲氧基异丁基异腈扫描,而对照组分别为84例(34%)和102例(42%)(无显著性差异)。在妊娠12至28周期间在全身麻醉下进行甲状旁腺切除术,未导致不良妊娠结局。治愈率为100%,而对照组为96%。
妊娠合并pHPT对母婴构成威胁。轻度疾病可能适合药物治疗,但对于中度至重度疾病,孕中期全身麻醉下的甲状旁腺切除术是安全的。无需使用电离辐射/MRI进行定位,因为在高容量多学科环境下的手术干预有良好的效果。关于该主题的指南将有助于临床医生。